In order to provide a possible explanation for the fact that the IL-32 promoter SNP did not influence the response of RA patients to therapy with adalimumab or etanercept in the first six months, we further thought to assess whether the genotype could affect the ex vivo response of PBMCs to various stimuli in the presence of etanercept or adalimumab. The gene discussed is IL32; the disease is rheumatoid arthritis.